Literature DB >> 24423611

Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.

Xin Shelley Wang1, Qiuling Shi, Nina D Shah, Cobi J Heijnen, Evan N Cohen, James M Reuben, Robert Z Orlowski, Muzaffar H Qazilbash, Valen E Johnson, Loretta A Williams, Tito R Mendoza, Charles S Cleeland.   

Abstract

PURPOSE: Increasing research suggests that inflammation mediates symptom development. In this longitudinal study, we examined inflammatory factors related to the development of high symptom burden during autologous hematopoietic stem cell transplant (AuSCT) for multiple myeloma. EXPERIMENTAL
DESIGN: Patients (n = 63) repeatedly reported symptom severity on the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM) and contributed blood samples periodically for up to 100 days after AuSCT for inflammatory marker assays. The temporal associations between serum inflammatory marker concentrations and symptom severity outcomes were examined by nonlinear mixed-effect modeling.
RESULTS: Fatigue, pain, disturbed sleep, lack of appetite, and drowsiness were consistently the most severe MDASI-MM symptoms during the study. Peak symptom severity occurred on day 8 after AuSCT, during white blood cell count nadir. Patterns of serum interleukin (IL)-6 (peak on day 9) and soluble IL-6 receptor (sIL-6R; nadir on day 8) expression paralleled symptom development over time (both P < 0.0001). By univariate analysis, serum IL-6, sIL-6R, IL-10, C-reactive protein, macrophage inflammatory protein (MIP)-1α, sIL-1R2, sIL-1RA, and soluble tumor necrosis factor receptor 1 were significantly related to the most severe symptoms during the first 30 days after AuSCT (all P < 0.05). By multivariate analysis, IL-6 (estimate = 0.170; P = 0.004) and MIP-1α (estimate = -0.172; P = 0.006) were temporally associated with the severity of the component symptom score.
CONCLUSIONS: Systemic inflammatory response was associated with high symptom burden during the acute phase of AuSCT. Additional research is needed to understand how the inflammatory response is mechanistically associated with symptom expression and whether suppression of this response can reduce symptoms without compromising tumor control. ©2014 AACR

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423611      PMCID: PMC3947467          DOI: 10.1158/1078-0432.CCR-13-2442

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Li Mao; Charles S Cleeland; Ritsuko R Komaki; Gary M Mobley; Zhongxing Liao
Journal:  Brain Behav Immun       Date:  2010-03-29       Impact factor: 7.217

Review 2.  The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review.

Authors:  Christian Schubert; Suzi Hong; Loki Natarajan; Paul J Mills; Joel E Dimsdale
Journal:  Brain Behav Immun       Date:  2006-12-18       Impact factor: 7.217

3.  Symptom burden in patients undergoing autologous stem-cell transplantation.

Authors:  K O Anderson; S A Giralt; T R Mendoza; J O Brown; J L Neumann; G M Mobley; X S Wang; C S Cleeland
Journal:  Bone Marrow Transplant       Date:  2007-04-16       Impact factor: 5.483

Review 4.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods.

Authors:  Lori D McLeod; Cheryl D Coon; Susan A Martin; Sheri E Fehnel; Ron D Hays
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

5.  Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.

Authors:  James M Reuben; Bang-Ning Lee; Changping Li; Jesus Gomez-Navarro; Viviana A Bozon; Charla A Parker; Ingrid M Hernandez; Carolina Gutierrez; Gabriel Lopez-Berestein; Luis H Camacho
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

Review 6.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Authors:  Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

Review 7.  Treatment of multiple myeloma: a comprehensive review.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Lymphoma Myeloma       Date:  2009-08

8.  Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation.

Authors:  Xin Shelley Wang; Qiuling Shi; Lori A Williams; Charles S Cleeland; Gary M Mobley; James M Reuben; Bang-Ning Lee; Sergio A Giralt
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

Review 10.  Cytokine inhibitors and graft-versus-host disease.

Authors:  J L Ferrara
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

View more
  32 in total

Review 1.  The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.

Authors:  Hemant S Murthy; William A Wood
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.

Authors:  Heather Landau; Kevin Wood; David J Chung; Guenther Koehne; Nikoletta Lendvai; Hani Hassoun; Alexander Lesokhin; Elizabeth Hoover; Junting Zheng; Sean M Devlin; Sergio Giralt
Journal:  Leuk Lymphoma       Date:  2016-01-12

3.  Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

Authors:  Jennifer M Knight; J Douglas Rizzo; Parameswaran Hari; Marcelo C Pasquini; Karen E Giles; Anita D'Souza; Brent R Logan; Mehdi Hamadani; Saurabh Chhabra; Binod Dhakal; Nirav Shah; Deepika Sriram; Mary M Horowitz; Steve W Cole
Journal:  Blood Adv       Date:  2020-02-11

4.  Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.

Authors:  Matthias Naegele; Monika Kirsch; Gabriele Ihorst; Katharina Fierz; Monika Engelhardt; Sabina De Geest
Journal:  Support Care Cancer       Date:  2017-09-16       Impact factor: 3.603

5.  Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial.

Authors:  Gary Deng; Sergio Giralt; David J Chung; Heather Landau; Jonathan Siman; Benjamin Search; Marci Coleton; Emily Vertosick; Nathan Shapiro; Christine Chien; Xin S Wang; Barrie Cassileth; Jun J Mao
Journal:  Support Care Cancer       Date:  2017-09-17       Impact factor: 3.603

Review 6.  The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms.

Authors:  Julienne E Bower
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

7.  Most multiple myeloma patients have low testosterone.

Authors:  Sonya John; Nidhi Sharma; Douglas W Sborov; Nita Williams; Desirée Jones; Don M Benson; Yvonne A Efebera; Ashley E Rosko; Jennifer Vincent; Craig C Hofmeister
Journal:  Leuk Lymphoma       Date:  2018-10-02

8.  Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study.

Authors:  Yichen Xu; Yanzhi Chen; Pingping Li; Xin Shelley Wang
Journal:  J Altern Complement Med       Date:  2015-04-28       Impact factor: 2.579

9.  Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

Authors:  Nina Shah; Qiuling Shi; Loretta A Williams; Tito R Mendoza; Xin Shelley Wang; James M Reuben; Patrick M Dougherty; Qaiser Bashir; Muzaffar H Qazilbash; Richard E Champlin; Charles S Cleeland; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-05       Impact factor: 5.742

10.  Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial.

Authors:  Gary Deng; Sergio Giralt; David J Chung; Heather Landau; Jonathan Siman; Qing S Li; Kaitlyn Lapen; Jun J Mao
Journal:  Pain Med       Date:  2020-03-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.